PsiOxus wins US$3.3m DTRA contract to develop biodefence vaccine adjuvants
Using its proprietary PolyMAP technology to increase antigenic response
PsiOxus Therapeutics has been awarded a US$3.3m contract from the US Defense Threat Reduction Agency (DTRA) to develop biodefence vaccine adjuvants.
PsiOxus will use its PolyMAP technology to help improve the safety and effectiveness of two vaccines candidates: the recombinant Protective Antigen (rPA) for Anthrax and the Venezuelan Equine Encephalopathy Virus (VEEV). PolyMAP is an immunotherapeutic platform that combines polymers with synthetic adjuvants to enhance the efficacy of vaccines.
Dr John Beadle, CEO of PsiOxus Therapeutics, said: ‘Adjuvant platforms are key to innovating and growing the global vaccine market, and we are confident that our immunotherapeutic platform PolyMAP, along with our oncolytic vaccines expertise and team of renowned scientists, will play a significant and long-term role in the future of the industry.’
The contract will support work over a three-year period in the US, as well as in the company’s new laboratory in Oxford, UK, which is equipped as a category two laboratory for the handling of live viruses.
